Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LYNPARZA Tablets 100mg, 150mg General Drug Use-results Study in Patients With BRCA Mutated HER2 Negative High Recurrent Risk Breast Cancer in the Adjuvant Setting

NCT05677308 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05677308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05677308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LYNPARZA Tablets 100mg, 150mg General Drug Use-results Study in Patients With BRCA Mutated HER2 Negative High Recurrent Risk Breast Cancer in the Adjuvant Setting
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
March 7, 2023
Completion date
February 18, 2026
Enrollment
61 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer